P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: Distribution and prognostic relevance

Abstract Young people (⩽40 years of age) with colorectal cancer (CRC) represent a distinct subgroup with more aggressive disease behaviour compared to older patients. We evaluate whether p53 and bcl-2 could be useful in identifying young patients at higher risk of tumour progression. We reviewed 134...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2008-06, Vol.44 (9), p.1217-1222
Main Authors: Torsello, A, Garufi, C, Cosimelli, M, Diodoro, M.G, Zeuli, M, Vanni, B, Campanella, C, D’Angelo, C, Sperduti, I, Donnorso, R. Perrone, Cognetti, F, Terzoli, E, Mottolese, M
Format: Article
Language:English
Subjects:
Adult
Age Factors
Aged
Aged, 80 and over
Apoptosis - physiology
bcl-2
Biological and medical sciences
Cell Transformation, Neoplastic - pathology
Chi-Square Distribution
Colorectal cancer
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
Female
Hematology, Oncology and Palliative Medicine
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Ki-67 Antigen - metabolism
Male
Medical sciences
Middle Aged
p53
Pharmacology. Drug treatments
Prognosis
Proto-Oncogene Proteins c-bcl-2 - metabolism
Tumor Suppressor Protein p53 - metabolism
Tumors
Young patients
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Young people (⩽40 years of age) with colorectal cancer (CRC) represent a distinct subgroup with more aggressive disease behaviour compared to older patients. We evaluate whether p53 and bcl-2 could be useful in identifying young patients at higher risk of tumour progression. We reviewed 1340 CRC patients with 58 patients ⩽40 years (4.2%). They had more frequent moderately or poorly differentiated mucinous adenocarcinomas (26% versus 12.3%, p = 0.03); higher advanced stage at diagnosis; shorter 5-year overall survival (49.8% versus 71%; p = 0.02); more frequent p53 positive (89.8% versus 72.6%, p < 0.05) and bcl-2 negative (88.0% versus 66.2%, p < 0.05) tumours; no difference in DNA content or proliferation indexes. Moreover, p53+ and bcl-2– resulted in being independent predictors of survival with shorter survival for the p53+/bcl-2– patients. Combining p53 and bcl-2, we could identify young CRC patients at higher risk of progression, who probably require development of a more sophisticated therapeutic approach based on identification of predictive factors.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2008.03.002